{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:38:20Z","timestamp":1790318300825,"version":"4.1.0"},"reference-count":95,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00765","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T05:31:59Z","timestamp":1589261519000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Update on Biology of Cutaneous T-Cell Lymphoma"],"prefix":"10.3389","volume":"10","author":[{"given":"Zaw H.","family":"Phyo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Shanbhag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Rozati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/ajh.24233","article-title":"Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Wilcox","year":"2016","journal-title":"Am J Hematol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1001\/archderm.143.7.854","article-title":"Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002","volume":"143","author":"Criscione","year":"2007","journal-title":"Arch Dermatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International society for cutaneous lymphomas\/European organisation for research and treatment of cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood."},{"key":"B5","first-page":"265","article-title":"Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study","volume":"132","author":"Salhany","year":"1988","journal-title":"Am J Pathol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1182\/blood-2008-05-154609","article-title":"Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation","volume":"112","author":"Arulogun","year":"2008","journal-title":"Blood."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J Clin Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and s\u00e9zary syndrome with variable CD30 expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1182\/blood-2009-11-251926","article-title":"Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors","volume":"116","author":"Campbell","year":"2010","journal-title":"Blood."},{"key":"B10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jaad.2003.12.052","article-title":"Familial mycosis fungoides: report of 6 kindreds and a study of the HLA system","volume":"52","author":"Hodak","year":"2005","journal-title":"J Am Acad Dermatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/1523-1747.ep12553615","article-title":"Association of HLA-DR5 with mycosis fungoides","volume":"80","author":"Safai","year":"1983","journal-title":"J Invest Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/1523-1747.ep12363352","article-title":"HLA-DR5 and DQB1*03 class II alleles are associated with cutaneous T-cell lymphoma","volume":"107","author":"Jackow","year":"1996","journal-title":"J Invest Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"7415","DOI":"10.1073\/pnas.77.12.7415","article-title":"Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma","volume":"77","author":"Poiesz","year":"1980","journal-title":"Proc Natl Acad Sci USA."},{"key":"B14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/BF02889936","article-title":"C-type virus-like particles specifically localized in langerhans cells and related cells of skin and lymph nodes of patients with mycosis fungoides and Sezary's syndrome. A morphological and biochemical study","volume":"31","author":"van der Loo","year":"1979","journal-title":"Virchows Arch B Cell Pathol Incl Mol Pathol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S0959-8049(02)00773-6","article-title":"Viral infection, atopy and mycosis fungoides: a European multicentre case-control study","volume":"39","author":"Morales","year":"2003","journal-title":"Eur J Cancer."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1002\/cncr.29301","article-title":"Identification of geographic clustering and regions spared by cutaneous T-cell lymphoma in Texas using 2 distinct cancer registries","volume":"121","author":"Litvinov","year":"2015","journal-title":"Cancer."},{"key":"B17","first-page":"591","article-title":"Exposure to chemicals, physical agents, and biologic agents in mycosis fungoides and the S\u00e9zary syndrome","volume":"63","author":"Fischmann","year":"1979","journal-title":"Cancer Treat Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/blood.V89.1.32.32_32_40","article-title":"Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion","volume":"89","author":"Jackow","year":"1997","journal-title":"Blood."},{"key":"B19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1365-2133.2008.08612.x","article-title":"Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sezary syndrome","volume":"159","author":"Talpur","year":"2008","journal-title":"Br J Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1365-2133.1995.tb02485.x","article-title":"Cutaneous colonization with staphylococci influences the disease activity of Sezary syndrome: a potential role for bacterial superantigens","volume":"133","author":"Tokura","year":"1995","journal-title":"Br J Dermatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.jid.2017.10.028","article-title":"Role of dysregulated cytokine signaling and bacterial triggers in the pathogenesis of cutaneous T-cell lymphoma","volume":"138","author":"Fanok","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1182\/blood.2018888107","article-title":"Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma","volume":"134","author":"Lindahl","year":"2019","journal-title":"Blood."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/ng.3370","article-title":"Genomic analysis of mycosis fungoides and S\u00e9zary syndrome identifies recurrent alterations in TNFR2","volume":"47","author":"Ungewickell","year":"2015","journal-title":"Nat Genet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of cutaneous T cell lymphoma","volume":"47","author":"Choi","year":"2015","journal-title":"Nat Genet."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T cell lymphoma and S\u00e9zary syndrome","volume":"47","author":"da Silva Almeida","year":"2015","journal-title":"Nat Genet."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1182\/blood.V99.8.2929.h8002929_2929_2939","article-title":"The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells","volume":"99","author":"Berger","year":"2002","journal-title":"Blood."},{"key":"B27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00281-016-0594-9","article-title":"Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover","volume":"39","author":"Krejsgaard","year":"2017","journal-title":"Semin Immunopathol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1182\/blood.2019002516","article-title":"Skin colonization by circulating neoplastic clones in cutaneous T-cell lymphoma","volume":"134","author":"Iyer","year":"2019","journal-title":"Blood."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1038\/jid.2014.206","article-title":"Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo","volume":"134","author":"Wu","year":"2014","journal-title":"J Invest Dermatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1182\/blood-2012-03-415638","article-title":"Mast cells play a protumorigenic role in primary cutaneous lymphoma","volume":"120","author":"Rabenhorst","year":"2012","journal-title":"Blood."},{"key":"B31","doi-asserted-by":"publisher","first-page":"586","DOI":"10.2340\/00015555-2623","article-title":"Placental growth factor and vascular endothelial growth factor together regulate tumour progression via increased vasculature in cutaneous T-cell lymphoma","volume":"97","author":"Miyagaki","year":"2017","journal-title":"Acta Derm Venereol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1182\/blood-2017-03-770982","article-title":"TCR-CXCR4 signaling stabilizes cytokine mRNA transcripts via a PREX1-Rac1 pathway: implications for CTC","volume":"130","author":"Kremer","year":"2017","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/jid.2014.284","article-title":"Malignant T cells secrete galectins and induce epidermal hyperproliferation and disorganized stratification in a skin model of cutaneous T-cell lymphoma","volume":"135","author":"Thode","year":"2015","journal-title":"J Invest Dermatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/ajh.21960","article-title":"Programmed death 1 is expressed in cutaneous infiltrates of mycosis fungoides and S\u00e9zary syndrome","volume":"86","author":"Wada","year":"2011","journal-title":"Am J Hematol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1001\/archdermatol.2012.2089","article-title":"Differential expression of programmed death-1 (PD-1) in S\u00e9zary syndrome and mycosis fungoides","volume":"148","author":"Cetin\u00f6zman","year":"2012","journal-title":"Arch Dermatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1158\/2326-6066.CIR-17-0270","article-title":"Primary T cells from cutaneous T-cell lymphoma skin explants display an exhausted immune checkpoint profile","volume":"6","author":"Querfeld","year":"2018","journal-title":"Cancer Immunol Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/sj.jid.5700029","article-title":"Increased expression of CTLA-4 in malignant T-cells from patients with mycosis fungoides \u2013 cutaneous T cell lymphoma","volume":"126","author":"Wong","year":"2006","journal-title":"J Invest Dermatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and S\u00e9zary syndrome: a multicenter phase II study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J Clin Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1001\/archderm.123.2.196","article-title":"A case-control study of possible causative factors in mycosis fungoides","volume":"123","author":"Tuyp","year":"1987","journal-title":"Arch Dermatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/1523-1747.ep12611877","article-title":"Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells","volume":"99","author":"Vowels","year":"1992","journal-title":"J Invest Dermatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1158\/1078-0432.CCR-07-0610","article-title":"Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma\/mycosis fungoides","volume":"14","author":"Chong","year":"2008","journal-title":"Clin Cancer Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1084\/jem.20021726","article-title":"Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma","volume":"197","author":"Kari","year":"2003","journal-title":"J Exp Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"6241","DOI":"10.1158\/0008-5472.CAN-16-0992","article-title":"Thymic stromal chemokine TSLP acts through Th2 cytokine production to induce cutaneous T-cell lymphoma","volume":"76","author":"Takahashi","year":"2016","journal-title":"Cancer Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"5507","DOI":"10.1158\/1078-0432.CCR-14-0707","article-title":"Deficient cutaneous antibacterial competence in cutaneous T-cell lymphomas: role of Th2-mediated biased Th17 function","volume":"20","author":"Wolk","year":"2014","journal-title":"Clin Cancer Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/ced.13777","article-title":"Secukinumab for treatment of psoriasis: does secukinumab precipitate or promote the presentation of cutaneous T-cell lymphoma?","volume":"44","author":"Yoo","year":"2019","journal-title":"Clin Exp Dermatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1182\/blood-2004-06-2181","article-title":"Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells","volume":"105","author":"Berger","year":"2005","journal-title":"Blood."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1158\/1078-0432.CCR-18-3309","article-title":"Single-cell profiling of cutaneous T-cell lymphoma reveals underlying heterogeneity associated with disease progression","volume":"25","author":"Borcherding","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1038\/ng.3444","article-title":"Genomic profiling of S\u00e9zary syndrome identifies alterations of key T cell signaling and differentiation genes","volume":"47","author":"Wang","year":"2015","journal-title":"Nat Genet."},{"key":"B52","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1182\/blood-2016-02-699843","article-title":"Candidate driver genes involved in genome maintenance and DNA repair in Sezary syndrome","volume":"127","author":"Woollard","year":"2016","journal-title":"Blood."},{"key":"B53","doi-asserted-by":"publisher","first-page":"39627","DOI":"10.18632\/oncotarget.17383","article-title":"Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sezary syndrome","volume":"8","author":"Izykowska","year":"2017","journal-title":"Oncotarget."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ncb2641","article-title":"p53 mutations in cancer","volume":"15","author":"Muller","year":"2013","journal-title":"Nat Cell Biol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1016\/j.jid.2018.06.176","article-title":"An integrated data resource for genomic analysis of cutaneous T-cell lymphoma","volume":"138","author":"Chang","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e0173171","DOI":"10.1371\/journal.pone.0173171","article-title":"TP53 alterations in primary and secondary S\u00e9zary syndrome: a diagnostic tool for the assessment of malignancy in patients with erythroderma","volume":"12","author":"Gros","year":"2017","journal-title":"PLoS ONE."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1182\/blood-2005-06-2536","article-title":"Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis","volume":"107","author":"Sors","year":"2006","journal-title":"Blood."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1182\/blood-2013-05-504308","article-title":"PLCG1 mutations in cutaneous T-cell lymphomas","volume":"123","author":"Vaqu\u00e9","year":"2014","journal-title":"Blood."},{"key":"B59","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J Clin Oncol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/sj.leu.2403385","article-title":"In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3","volume":"18","author":"Sommer","year":"2004","journal-title":"Leukemia."},{"key":"B61","doi-asserted-by":"publisher","first-page":"342","DOI":"10.2478\/s11658-010-0008-2","article-title":"STAT3 knockdown by siRNA induces apoptosis in human cutaneous T-cell lymphoma line Hut78 via downregulation of Bcl-xL","volume":"15","author":"Verma","year":"2010","journal-title":"Cell Mol Biol Lett."},{"key":"B62","doi-asserted-by":"publisher","first-page":"F1000","DOI":"10.12688\/f1000research.8829.1","article-title":"An overview of cutaneous T cell lymphomas","volume":"5","author":"Bagherani","year":"2016","journal-title":"F1000Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1182\/blood-2017-02-768234","article-title":"Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E)","volume":"130","author":"Park","year":"2017","journal-title":"Blood."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1182\/blood-2015-08-662353","article-title":"Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma","volume":"127","author":"Willerslev-Olsen","year":"2016","journal-title":"Blood."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1158\/0008-5472.CAN-07-6398","article-title":"Novel and highly recurrent chromosomal alterations in S\u00e9zary syndrome","volume":"68","author":"Vermeer","year":"2008","journal-title":"Cancer Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1038\/jid.2010.8","article-title":"Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes","volume":"130","author":"Laharanne","year":"2010","journal-title":"J Invest Dermatol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/jid.2011.254","article-title":"Characterization of the DNA copy-number genome in the blood of cutaneous T-cell lymphoma patients","volume":"132","author":"Lin","year":"2012","journal-title":"J Invest Dermatol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/carcin\/bgp220","article-title":"Epigenetics in cancer","volume":"31","author":"Sharma","year":"2010","journal-title":"Carcinogenesis."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.4161\/15592294.2014.971580","article-title":"Chromatin regulation: how complex does it get?","volume":"9","author":"Meier","year":"2014","journal-title":"Epigenetics."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist."},{"key":"B71","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1586\/era.10.88","article-title":"Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors","volume":"10","author":"Grant","year":"2010","journal-title":"Expert Rev Anticancer Ther."},{"key":"B72","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/nrd3179","article-title":"Targeting microRNAs in cancer: rationale, strategies and challenges","volume":"9","author":"Garzon","year":"2010","journal-title":"Nat Rev Drug Discov."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1038\/cddis.2011.32","article-title":"MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in S\u00e9zary syndrome","volume":"2","author":"Narducci","year":"2011","journal-title":"Cell Death Dis."},{"key":"B74","doi-asserted-by":"publisher","first-page":"5891","DOI":"10.1182\/blood-2011-06-358382","article-title":"Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL)","volume":"118","author":"Ralfkiaer","year":"2011","journal-title":"Blood."},{"key":"B75","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.molonc.2011.02.003","article-title":"miRNA expression profiling of mycosis fungoides","volume":"5","author":"van Kester","year":"2011","journal-title":"Mol Oncol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1365-2133.2011.10669.x","article-title":"Altered microRNA expression in mycosis fungoides","volume":"166","author":"Maj","year":"2012","journal-title":"Br J Dermatol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.4161\/cc.24987","article-title":"STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma","volume":"12","author":"Kopp","year":"2013","journal-title":"Cell Cycle."},{"key":"B78","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/bjh.15547","article-title":"Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma","volume":"183","author":"Seto","year":"2018","journal-title":"Br J Haematol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1200\/JCO.2018.36.15_suppl.2511","article-title":"Ph 1 study of MRG-106, an inhibitor of miR-155","volume":"36","author":"Foss","year":"2018","journal-title":"J Clin Oncol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1182\/blood-2017-06-788950","article-title":"Prognostic miRNA classifier in early-stage mycosis fungoides: development and validation in a Danish nationwide study","volume":"131","author":"Lindahl","year":"2018","journal-title":"Blood."},{"key":"B81","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/j.jid.2018.03.1500","article-title":"MicroRNA signatures in diagnosis and prognosis of cutaneous T-cell lymphoma","volume":"138","author":"Shen","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41591-018-0008-8","article-title":"Transcript-indexed ATAC-seq for precision immune profiling","volume":"24","author":"Satpathy","year":"2018","journal-title":"Nat Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"4443","DOI":"10.1158\/1078-0432.CCR-19-0148","article-title":"Single-cell lymphocyte heterogeneity in advanced cutaneous T-cell lymphoma skin tumors","volume":"25","author":"Gaydosik","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B84","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1182\/bloodadvances.2018022608","article-title":"Single-cell heterogeneity in Sezary syndrome","volume":"2","author":"Buus","year":"2018","journal-title":"Blood Adv."},{"key":"B85","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-15-1435","article-title":"Romidepsin and azacitidine synergize in their epigenetic modulatory effects to induce apoptosis in CTCL","volume":"22","author":"Rozati","year":"2016","journal-title":"Clin Cancer Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"29193","DOI":"10.18632\/oncotarget.25670","article-title":"BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition","volume":"9","author":"Kim","year":"2018","journal-title":"Oncotarget."},{"key":"B87","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/j.jaad.2011.06.043","article-title":"Romidepsin and interferon gamma: a novel combination for refractory cutaneous T-cell lymphoma","volume":"68","author":"Samimi","year":"2013","journal-title":"J Am Acad Dermatol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1158\/1078-0432.CCR-19-2152","article-title":"Romidepsin plus liposomal doxorubicin is safe and effective in patients with relapsed or refractory T-cell lymphoma: results of a phase I dose-escalation study","volume":"26","author":"Vu","year":"2020","journal-title":"Clin Cancer Res."},{"key":"B89","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1182\/blood.2019001545","article-title":"Combined inhibition of Bcl-2 and NF\u03baB synergistically induces cell death in cutaneous T-cell lymphoma","volume":"134","author":"Froehlich","year":"2019","journal-title":"Blood."},{"key":"B90","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.neo.2018.11.006","article-title":"Preclinical studies support combined inhibition of BET family proteins and histone deacetylases as epigenetic therapy for cutaneous T-cell lymphoma","volume":"21","author":"Zhao","year":"2019","journal-title":"Neoplasia."},{"key":"B91","doi-asserted-by":"publisher","first-page":"13520","DOI":"10.1073\/pnas.0804295105","article-title":"Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways","volume":"105","author":"Lenz","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"key":"B92","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature20598","article-title":"A 17-gene stemness score for rapid determination of risk in acute leukaemia","volume":"540","author":"Ng","year":"2016","journal-title":"Nature."},{"key":"B93","doi-asserted-by":"publisher","first-page":"5474602","DOI":"10.1155\/2016\/5474602","article-title":"CAR T cell therapy: a game changer in cancer treatment","volume":"2016","author":"Alm\u00e5sbak","year":"2016","journal-title":"J Immunol Res."},{"key":"B94","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00765\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T05:32:02Z","timestamp":1589261522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00765\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,12]]},"references-count":95,"alternative-id":["10.3389\/fonc.2020.00765"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00765","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,12]]},"article-number":"765"}}